VALSARTAN-HYDROCHLOROTHIAZIDE MARKET

INTRODUCTION

A combo drug called valsartan-hydrochlorothiazide is used to treat high blood pressure. (hypertension). Valsartan, a member of the angiotensin receptor blocker (ARB) class of medications, and hydrochlorothiazide, a diuretic or "water pill," are its two active components.

 While hydrochlorothiazide aids in lowering the body's salt and water content, which also decreases blood pressure, valsartan acts by relaxing blood vessels to lower blood pressure.

This drug should be taken at the same time every day, once daily, with or without meals. It's crucial to adhere to your doctor's dosage recommendations and to never stop taking this medicine without first talking to your doctor.

Dizziness, headaches, weariness, and increased urination are typical adverse effects of valsartan-hydrochlorothiazide. Additionally, some people may get more severe adverse effects from it, such as kidney issues or allergic responses.

Before beginning therapy with valsartan-hydrochlorothiazide, it is crucial to discuss any potential dangers and benefits with your doctor. This is true of any medicine.

VALSARTAN-HYDROCHLOROTHIAZIDE MARKET SIZE AND FORECAST

Global valsartan-hydrochlorothiazide market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

VALSARTAN-HYDROCHLOROTHIAZIDE MARKET RECENT DEVELOPMENT 

Ex forge HCT (amlodipine, valsartan, hydrochlorothiazide), the only blood pressure (BP) treatment that combines three drugs in a single pill, has been approved by the US Food and Drug Administration (FDA).

Ex forge HCT is a crucial new alternative for individuals who have tried using dual combinations of these blood pressure drugs without success. It combines the most commonly prescribed calcium channel blocker, angiotensin receptor blocker, and diuretic in one pill.

Patients with moderate to severe hypertension can experience proven success with Ex forge HCT. In a clinical trial, the maximum dose of E forge HCT (amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg) significantly reduced systolic and diastolic blood pressure when compared to all dual combinations of its components at the same doses (valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg.

Ex forge HCT significantly lowers systolic and diastolic blood pressure compared to valsartan/hydrochlorothiazide, amlodipine/valsartan, and amlodipine/hydrochlorothiazide by 7.6/5.0 mmHg, 6.2/3.3 mmHg, and 8.2/5.3 mmHg, respectively.

There is also an unmeasured placebo impact in these outcomes. Ambulatory blood pressure monitoring revealed that Exforge HCT's blood pressure-lowering impact persisted for the entire 24-hour period.

VALSARTAN-HYDROCHLOROTHIAZIDE MARKET COMPANY PROFILE

• Novartis Pharmaceuticals
• Mylan Pharmaceuticals 
• Teva Pharmaceuticals 
• Zydus Pharmaceuticals 
• Lupin Pharmaceuticals 
• Torrent Pharmaceuticals 
• Aurobindo Pharma 

THIS VALSARTAN-HYDROCHLOROTHIAZIDE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many valsartan-hydrochlorothiazide are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global valsartan-hydrochlorothiazide and key vendor selection criteria
3. Where is the valsartan-hydrochlorothiazide manufactured? What is the average margin per unit?
4. Market share of Global valsartan-hydrochlorothiazide market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global valsartan-hydrochlorothiazide in-house
6. key predictions for next 5 years in Global valsartan-hydrochlorothiazide market
7. Average B-2-B valsartan-hydrochlorothiazide market price in all segments
8. Latest trends in valsartan-hydrochlorothiazide market, by every market segment
9. The market size (both volume and value) of the valsartan-hydrochlorothiazide market in 2024-2030 and every year in between?
10. Production breakup of valsartan-hydrochlorothiazide market, by suppliers and their OEM relationship